Literature DB >> 9120501

Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients.

M Drlicek1, G Bianchi, G Bogliun, B Casati, W Grisold, C Kolig, U Liszka-Setinek, L Marzorati, E Wondrusch, G Cavaletti.   

Abstract

In recent years several authors have described a close correlation between circulating antineuronal antibodies of different types and the occurrence of paraneoplastic neurological syndromes. Because this has not been widely accepted, we screened 300 serum samples from 181 ovarian cancer patients for the presence of circulating antineuronal antibodies by immunofluorescence. The findings were confirmed by immunoblotting. In 11 patients circulating antineuronal antibodies were detected. In 4 patients they were classified as anti-Yo and in 7 as anti-Ri, titres ranging from 1:400 to 1: 204,800. All the patients underwent thorough neurological and neurophysiological investigations, with special regard to paraneoplastic syndrome. None of them had symptoms pointing to a paraneoplastic neurological syndrome, although patients were followed up to 2 years after the first examination. Thus the frequency of circulating antineuronal antibodies in ovarian cancer patients is higher than the frequency of paraneoplastic syndromes, and antibody positivity does not necessarily lead to the appearance of a neurological paraneoplastic syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120501     DOI: 10.1007/s004150050054

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Update on paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Oncologist       Date:  2010-05-17

Review 2.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 3.  Diagnosis and management of paraneoplastic neurologic disorders.

Authors:  Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 4.  Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.

Authors:  Eric Lancaster; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

5.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

Review 6.  Paraneoplastic movement disorders.

Authors:  Shyamal H Mehta; John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

7.  Autoantibodies against the Ca(2+)-binding protein recoverin in blood sera of patients with various oncological diseases.

Authors:  Marina S Savchenko; Maria A Goncharskaia; Elena E Skorikova; Stefan B Eichmüller; Nikolay E Kushlinsky; Alexandr V Bazhin; Pavel P Philippov
Journal:  Oncol Lett       Date:  2011-10-31       Impact factor: 2.967

8.  Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.

Authors:  S E Monstad; A Storstein; A Dørum; A Knudsen; P E Lønning; H B Salvesen; J H Aarseth; C A Vedeler
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

9.  Acute onset paraneoplastic cerebellar degeneration.

Authors:  Anastasios Bonakis; Sokratis G Papageorgiou; Dimitrios Mandellos; Eleni Galani; Nikolaos Kalfakis
Journal:  J Neurooncol       Date:  2007-03-23       Impact factor: 4.506

Review 10.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.